PMS19 - A BUDGET IMPACT ANALYSIS OF INTRODUCING A FORCED TREATMENT PATHWAY USING THE LOWEST PRICED ANTI-TUMOR NECROSIS FACTOR AGENT FOR RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN THE PHILIPPINES
Abstract
Authors
M. Tee C.A. Tee